TOBRACEF


A powerful combination of Ceftazidime & Tobramycin. Effective against MDR Gram Negative Pathogens. Highly potent against Gram negative P. seruginosa, S. aureus, K. pneumonia

Indications

  • Tobracef is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following disease: -
  • Lower respiratory tract infections caused by Pseudomonas aeruginosa (susceptible and multiple drug resistant strains [MDR]), Klebsiella species, Enterobacter species, Serratia species Escherichia coli, Staphylococcus aureus (penicillinases and non-penicillinases producing strains)
  • Empirical therapy in hospital-acquired pneumonia (HAP) or nosocomial pneumonia, ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia (HCAP) and is also effective in carbapenem resistant pneumonia infection
  • Empirical therapy in burns

Product Presentation

1.120 g, 560 mg powder of injection

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top